Project Grant HT94252411061
Award Date
9/30/24
Completion Date
9/29/28
Dollars Obligated
$7.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10005, USA
Similar Awards
The Defense Health Agency awarded a $215,429 Project Grant to The Global Alliance For TB Drug Development Inc. (TB Alliance) to investigate a host-directed proteolysis-targeting chimera (PROTAC) approach for targeting intracellular Mycobacterium tuberculosis. This two-year grant, running from July 2024 to July 2026, supports TB Alliance's research and development efforts to accelerate the development of new tuberculosis (TB) drugs and treatment regimens. The funding falls under the Military...
This $817,405 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop new 3-4 drug regimens for the treatment of drug-sensitive and drug-resistant tuberculosis (TB). The primary goals are to (1) manufacture and characterize dry powder formulations of the spectinamide compound LEE-1810 for inhalation delivery, (2) determine the optimal dose and dosing frequency of the BPAS...
This federal Cooperative Agreement award, funded by the U.S. Agency for International Development (USAID) under the USAID Foreign Assistance for Programs Overseas (CFDA 98.001) program, is intended to scale up and improve the management of drug-resistant tuberculosis (DR-TB) in USAID-supported countries. The $287,878,180 award, effective from October 1, 2024 to September 30, 2029, will focus on expanding access to high-quality DR-TB treatment services and providing specialized technical...
This $1,350,312 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research program supports the development of a rapid, phenotypic drug susceptibility testing (DST) system for tuberculosis (TB). The primary goal is to design and optimize a novel, trehalose-based DST (TRE-DST) that can accurately diagnose TB drug resistance, including for first- and second-line TB drugs. This includes developing and...
This federal Project Grant award of $787,171, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of new antituberculosis (TB) compounds based on 1,2,4-triazole and pyrrolidine scaffolds. The primary awardee, Washington University in St. Louis, aims to demonstrate preclinical proof-of-concept for these compounds, optimize lead candidates for pharmacological properties, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop novel pro-apoptotic (cell death-inducing) small molecule therapies as a host-directed treatment for pulmonary tuberculosis (TB). The $817,941 award to The Johns Hopkins University will leverage cutting-edge imaging technologies and high-dimensional immunophenotyping to gain mechanistic insights on how...
This federal Project Grant award of $1,185,782.00, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to transform global tuberculosis (TB) research by accelerating the study of human TB lung tissue. The primary goals are to provide two key services to the TB research community: (1) performing pathological, cellular, structural, and/or genetic analysis of resected human TB or postmortem...
This $749,414 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The primary awardee, The Ohio State University, is conducting research to investigate the role of the macrophage efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis and its impact on tuberculosis (TB) treatment duration. The research aims to: 1) define the role of MDR1 in M.TB survival in macrophages;...
The federal Project Grant award R21AI186928, titled "RIFAPENTINE IN HIGH DOSES IN PREGNANCY WITH TB (RADIANT-MOMS) STUDY", is funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $166,541 award will be used by the Trustees of Columbia University in the City of New York to conduct research on optimizing tuberculosis (TB) treatment for pregnant and breastfeeding people, a population...
This $246,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of lung repair and regeneration pathways in tuberculosis (TB). The primary objectives are to determine the functional role of the bone morphogenetic protein (BMP) signaling pathway in controlling TB infection and reactivation, as well as characterize the cellular mechanisms...